Circadian gating of lysosomal cathepsin L activity controls SASP clearance and extracellular matrix remodeling as a core anti-aging mechanism
Hypothesis
The circadian clock directly times the expression and activity of the lysosomal protease cathepsin L (CTSL) to drive rhythmic clearance of senescence‑associated secretory phenotype (SASP) factors and to limit collagen cross‑linking via lysyl oxidase (LOX). Loss of this temporal gating—whether through genetic disruption of BMAL1/CLOCK or age‑related dampening of clock amplitude—results in sustained SASP accumulation, aberrant extracellular matrix (ECM) stiffening, and chronic inflammation, thereby accelerating multiple SENS hallmarks of aging.
Mechanistic Rationale
- Transcriptional control – BMAL1/CLOCK heterodimers bind E‑box elements in the promoter of the Ctsl gene, driving a ~24‑hour oscillation in cathepsin L mRNA and protein levels in liver, muscle, and skin (supported by chromatin‑seq data showing rhythmic BMAL1 occupancy at lysosomal gene loci).
- Proteostatic flux – Cathepsin L activity peaks during the active phase, coinciding with heightened autophagic flux, enabling selective degradation of secreted SASP components (e.g., IL‑6, MMP‑9) before they can engage downstream receptors.
- ECM feedback – When cathepsin L rhythm is blunted, SASP proteases persist, activating latent TGF‑β and upregulating LOX transcription via SMAD signaling, leading to increased collagen cross‑linking and tissue stiffening.
- Age‑related decoupling – In aged tissues, reduced BMAL1 binding (as observed in epidermal BMAL1/YAP re‑programming) diminishes Ctsl oscillation, uncoupling SASP clearance from the circadian cycle and creating a feed‑forward loop of inflammation and ECM remodeling.
Testable Predictions
- Prediction 1: In wild‑type mice, cathepsin L activity in liver and skeletal muscle will show a robust circadian rhythm (peak ~ZT6‑ZT10) that is abolished in Bmal1‑KO or Clock‑Δ19 mutants.
- Prediction 2: Pharmacological enhancement of cathepsin L activity at the predicted peak time (e.g., timed delivery of a cathepsin L activator) will reduce circulating SASP factors and lower tissue LOX‑mediated cross‑links compared with vehicle or mistimed dosing.
- Prediction 3: Chronic mistimed feeding (e.g., high‑fat diet ad libitum) will dampen Ctsl rhythm, accelerate SASP accumulation, and shorten lifespan; rescuing the rhythm via time‑restricted feeding will restore cathepsin L oscillation and improve healthspan.
Experimental Approach
- In vivo: Use Bmal1 floxed mice crossed with tissue‑specific Cre drivers (muscle, liver, epidermis) to generate conditional knockouts; monitor cathepsin L activity via fluorogenic substrates every 4 h over 48 h. Simultaneously measure SASP cytokines (ELISA), LOX activity (hydroxylysine pyridinoline assay), and collagen cross‑linking (second‑harmonic generation imaging).
- Intervention: Administer a cathepsin L‑activating peptide (or small‑molecule allosteric activator) either at the predicted activity peak or at the trough; assess SASP burden, ECM stiffness (atomic force microscopy), and functional outcomes (grip strength, treadmill endurance, skin elasticity).
- Human relevance: Analyze peripheral blood mononuclear cells from young vs. older volunteers for circadian cathepsin L mRNA (qPCR) and activity; correlate with plasma SASP markers and pulse‑wave velocity (arterial stiffness proxy).
Falsifiability
If cathepsin L activity does not exhibit a circadian rhythm in wild‑type tissues, or if timed activation fails to reduce SASP/LOX signatures despite robust target engagement, the hypothesis would be refuted. Conversely, confirmation would position circadian regulation of lysosomal proteostasis as a direct, repair‑oriented anti‑aging lever that can be harnessed via chronopharmacology.